• Protease Inhibitor Cocktail EDTA-Free: Safeguarding Lysosoma

  2026-05-01

  Explore the critical role of Protease Inhibitor Cocktail EDTA-Free in preserving protein integrity during extraction and advanced assays. This article uniquely connects lysosomal repair mechanisms with practical proteomics, offering new scientific insights beyond standard workflow recommendations.

• SN-38 and Camptothecin Block FUBP1–FUSE Binding in Cancer Ce

  2026-05-01

  This study uncovers a novel mechanism by which camptothecin and its analog SN-38—best known as DNA topoisomerase I inhibitors—directly inhibit the binding of the oncoprotein FUBP1 to its DNA target, FUSE, in tumor cells. These findings broaden our understanding of SN-38's action in advanced cancer models and suggest dual-pathway targeting as a promising strategy in colon and hepatocellular carcinoma research.

• Fucoidan Mitigates Irinotecan-Induced Steatohepatitis via Gu

  2026-04-30

  This study illuminates the mechanisms behind irinotecan (CPT-11)-induced steatohepatitis, identifying gut barrier disruption and neutrophil extracellular trap (NET) formation as central drivers of hepatotoxicity. Notably, fucoidan was shown to restore gut barrier function and suppress hepatic inflammation, offering a targeted strategy to mitigate chemotherapy-associated liver injury.

• SN-38 Inhibits FUBP1-DNA Interaction: New Mechanism in Colon

  2026-04-30

  This study reveals that 7-Ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan, directly disrupts the binding of the oncogenic transcriptional regulator FUBP1 to its DNA target sequence, FUSE, in addition to its established role as a topoisomerase I inhibitor. These findings highlight a dual mechanism of action, suggesting new avenues for targeting advanced colon and hepatocellular carcinoma models.

• One-step TUNEL Cy5 Apoptosis Detection Kit: Precision in Pro

  2026-04-29

  Unlock rapid, high-sensitivity detection of apoptotic DNA fragmentation in both tissue sections and cultured cells with the One-step TUNEL Cy5 Apoptosis Detection Kit. This APExBIO solution streamlines workflow, ensures robust Cy5 fluorescence, and empowers advanced research into apoptosis, energy metabolism, and immune regulation.

• Gingerenone A Restores Sunitinib Sensitivity via LDHA Inhibi

  2026-04-29

  This study reveals that gingerenone A, a phenolic compound from Zingiber officinale, suppresses LDHA-mediated glycolysis to overcome sunitinib resistance in renal cell carcinoma. By disrupting metabolic and angiogenic signaling, gingerenone A enhances sunitinib efficacy and offers a promising metabolic adjuvant strategy.

• G-1: Selective GPR30 Agonist for Disease Modeling & Signal D

  2026-04-28

  G-1 (CAS 881639-98-1) from APExBIO empowers precise, rapid modulation of GPR30 signaling in immune, cardiovascular, and oncology models. Its unmatched selectivity and nanomolar potency drive reproducible, translational insights where non-classical estrogen pathways are pivotal.

• BMX-IN-1: Mechanistic Insights and Protocol Guidance for BMX

  2026-04-28

  Explore how BMX-IN-1, a leading BMX kinase inhibitor, enables advanced mechanistic studies in cancer and infectious disease models. This article delivers unique technical depth and practical assay guidance, bridging current knowledge gaps.

• TP53-Dependent DHODH Inhibition in Nasopharyngeal Carcinoma

  2026-04-27

  Dong et al. reveal that targeting DHODH, a key enzyme in pyrimidine biosynthesis, suppresses nasopharyngeal carcinoma via a TP53-dependent mechanism. This work advances understanding of cancer metabolism and highlights the therapeutic promise of DHODH inhibition in tumors with intact TP53 signaling.

• Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP): Reliable Report

  2026-04-27

  This article addresses core laboratory challenges in gene expression and cell viability assays, highlighting how Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP) (SKU R1005) delivers reproducible, sensitive, and low-immunogenicity readouts. Scenario-driven Q&A blocks provide evidence-based guidance for bench scientists, offering protocol optimization, data interpretation, and practical vendor selection insights.

• Jasplakinolide as a Precision Tool for Quantitative Actin Dy

  2026-04-26

  Explore the advanced utility of Jasplakinolide as a potent actin polymerization inducer for quantitative cytoskeletal studies. This in-depth review reveals unique assay design strategies and protocol parameters to maximize data fidelity in actin cytoskeleton research.

• ML385: Precision NRF2 Inhibition for Resistance and Ferropto

  2026-04-25

  Explore how ML385, a selective NRF2 inhibitor, enables researchers to dissect therapeutic resistance and ferroptosis with unprecedented precision. This article reveals practical assay strategies, protocol optimization, and unique insight from translational models—bridging the gap between mechanistic depth and real-world research utility.

• Distinct DNA Cleavage Mechanisms of Gepotidacin vs. Fluoroqu

  2026-04-24

  This study elucidates the structural and mechanistic basis for gepotidacin's inhibition of Staphylococcus aureus DNA gyrase, demonstrating a unique single-stranded DNA cleavage profile that differs from fluoroquinolones like moxifloxacin. The findings clarify resistance mechanisms and inform the design of next-generation antibacterial agents.

• Cy5-UTP: Precision RNA Labeling for Advanced In Vitro Applic

  2026-04-24

  Cy5-UTP (Cyanine 5-uridine triphosphate) empowers direct, high-sensitivity fluorescent RNA probe synthesis—enabling single-molecule imaging, robust FISH, and dual-color analyses. Its proven compatibility with T7 RNA polymerase and orange-red emission make it the gold standard for streamlined and multiplexed RNA labeling workflows.

• Distinct Mechanisms of Chuanxiong Cortex and Pith in CHD The

  2026-04-23

  This study by Li et al. applies advanced SPME-GC×GC-MS and network pharmacology to distinguish the preventive mechanisms of the cortex and pith of Ligusticum chuanxiong in coronary heart disease (CHD). The findings highlight unique bioactive profiles and molecular targets, offering new insights for targeted CHD interventions.

16272 records 1/1085 page Next 12345 下5页 Last page